Incyte (INCY) Announces Multiple Presentations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
TD Cowen Reiterates Buy Rating on Incyte (INCY)
June 4, 2025 6:29 AM EDTTD Cowen analyst Marc Frahm reiterated a Buy rating and $86.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "EHA Abstract Shows Promising Efficacy For mCALR In ET We are encouraged by initial data in ET which show '989 driving rapid and robust improvements in platelet counts which met the threshold for hematologic response in the majority of cases. Notably, these outcomes are consistent with several blog posts in online forums which had described deep... More
JPMorgan Reiterates Neutral Rating on Incyte (INCY)
June 3, 2025 3:53 PM EDTJPMorgan analyst Jessica Fye reiterated a Neutral rating and $68.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "Earlier today, closely watched mCALR data (INCA33989) were shared from the first-in-human phase I trial in a late-breaker abstract for EHA (link here). This includes dose-escalation data only in patients with essential thrombocythemia (ET) who were resistant/intolerant to prior therapy and no data were shared in MF. Even though mgmt previously mentioned ET and MF updates might come separately, we... More
Citi Reiterates Buy Rating on Incyte (INCY)
June 3, 2025 1:01 PM EDTCiti analyst David Lebowitz reiterated a Buy rating and $88.00 price target on Incyte (NASDAQ: INCY).
The analyst comments "Incyte announced today that proof-of-concept data for its mCALR inhibitor INCA33989 (abstract HERE) in treating essential thrombocythemia (ET) was accepted as a late-breaking... More
